Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

sonderdruck aus: BMC cancer | 2018

von Bubnoff, N. | Ihorst, G. | Grishina, O. | +5